Quark looks to Tel Aviv for $20 million IPO while BioLineRx heads stateside
This article was originally published in Scrip
Executive Summary
Companies need to raise finance wherever they can get it, even if it means they cross each others paths. US siRNA technology firm Quark Pharmaceuticals has filed plans to float on the Tel Aviv stock exchange in a $20 million IPO, while, the Israeli biopharmaceutical company BioLineRx hopes to raise $31 million by listing on Nasdaq.